Profile data is unavailable for this security.
About the company
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
- Revenue in JPY (TTM)1.77tn
- Net income in JPY54.75bn
- Incorporated1939
- Employees14.75k
- LocationAstellas Pharma Inc2-5-1, Nihombashihon-choCHUO-KU 103-8411JapanJPN
- Phone+81 332443000
- Websitehttps://www.astellas.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Santen Pharmaceutical Co Ltd | 302.56bn | 26.13bn | 605.73bn | 3.74k | 22.65 | 2.01 | 13.64 | 2.00 | 73.46 | 73.46 | 846.14 | 827.65 | 0.7238 | 2.58 | 3.68 | 80,812,770.00 | 6.25 | 3.31 | 7.77 | 4.10 | 57.92 | 59.73 | 8.64 | 5.21 | 1.97 | 5.38 | 0.1639 | 82.21 | 8.22 | 5.23 | 278.09 | -3.58 | 5.10 | 4.88 |
| Rohto Pharmaceutical Co Ltd | 282.05bn | 27.26bn | 648.31bn | 7.26k | 23.03 | 2.47 | 17.82 | 2.30 | 119.22 | 119.22 | 1,233.69 | 1,109.16 | 0.759 | 2.18 | 4.12 | 38,855,630.00 | 7.37 | 8.54 | 10.29 | 11.79 | 57.38 | 58.59 | 9.71 | 10.30 | 1.29 | -- | 0.1442 | 19.39 | 13.48 | 8.09 | 17.28 | 25.85 | 5.20 | 18.61 |
| Ono Pharmaceutical Co Ltd | 484.30bn | 95.13bn | 870.97bn | 3.85k | 8.68 | 1.05 | 7.69 | 1.80 | 201.26 | 201.26 | 1,026.05 | 1,665.85 | 0.4987 | 2.37 | 3.47 | 125,694,000.00 | 9.80 | 11.95 | 11.16 | 13.73 | 75.38 | 74.11 | 19.65 | 23.89 | 2.80 | -- | 0.1702 | 32.25 | 12.41 | 11.73 | 13.53 | 19.95 | -6.79 | 12.20 |
| Kyowa Kirin Co Ltd | 498.98bn | 83.53bn | 1.34tn | 5.97k | 16.25 | 1.60 | 12.39 | 2.68 | 156.64 | 156.64 | 936.10 | 1,591.79 | 0.4878 | 1.78 | 3.92 | 83,524,780.00 | 8.17 | 6.28 | 9.50 | 7.08 | 74.30 | 75.45 | 16.74 | 14.96 | 3.06 | -- | 0.0276 | 47.25 | 11.01 | 10.25 | 51.55 | 10.52 | 10.28 | 9.86 |
| Eisai Co Ltd | 753.22bn | 40.97bn | 1.37tn | 11.07k | 32.22 | 1.59 | 16.59 | 1.82 | 143.36 | 143.36 | 2,634.81 | 2,905.11 | 0.5673 | 0.8933 | 3.89 | 68,060,180.00 | 3.21 | 5.29 | 4.32 | 7.16 | 79.12 | 76.91 | 5.67 | 8.68 | 1.50 | -- | 0.1781 | 74.13 | -0.3561 | 2.90 | -23.50 | -7.72 | -2.11 | 1.30 |
| Shionogi & Co Ltd | 418.51bn | 154.57bn | 1.83tn | 4.96k | 11.39 | 1.35 | 10.59 | 4.38 | 180.74 | 180.74 | 489.15 | 1,519.70 | 0.292 | 0.9189 | 2.94 | 84,393,830.00 | 10.69 | 12.57 | 11.94 | 14.24 | 85.70 | 84.43 | 36.62 | 37.91 | 6.48 | -- | 0.0088 | 26.77 | 1.97 | 3.41 | -12.40 | 3.38 | 2.17 | 11.22 |
| Astellas Pharma Inc | 1.77tn | 54.75bn | 2.84tn | 14.75k | 51.68 | 1.84 | 11.35 | 1.61 | 30.42 | 30.42 | 986.34 | 854.61 | 0.5060 | 1.36 | 3.39 | 120,113,500.00 | 1.56 | 4.59 | 2.31 | 6.61 | 81.78 | 80.53 | 3.09 | 7.98 | 0.8623 | 15.32 | 0.3774 | 86.61 | 5.60 | 4.19 | -82.73 | -40.17 | 9.62 | 13.00 |
| Otsuka Holdings Co Ltd | 2.27tn | 151.58bn | 4.99tn | 34.39k | 32.03 | 1.93 | 18.98 | 2.20 | 279.51 | 279.51 | 4,183.34 | 4,641.15 | 0.647 | 2.40 | 4.68 | 65,998,690.00 | 4.42 | 4.80 | 5.59 | 5.88 | 71.42 | 68.21 | 6.84 | 8.36 | 1.53 | -- | 0.1173 | 42.16 | 16.14 | 9.33 | -9.18 | 8.07 | 9.27 | 1.92 |
| Takeda Pharmaceutical Co Ltd | 4.55tn | 289.99bn | 6.56tn | 49.28k | 22.66 | 0.9439 | 6.25 | 1.44 | 181.90 | 181.90 | 2,862.68 | 4,365.91 | 0.3088 | 1.31 | 6.25 | 92,248,190.00 | 1.97 | 1.65 | 2.35 | 1.97 | 66.05 | 68.05 | 6.38 | 6.06 | 0.7739 | 3.08 | 0.4219 | 128.42 | 5.87 | 15.25 | -54.56 | 1.28 | 29.09 | 0.8735 |
| Daiichi Sankyo Co Ltd | 1.76tn | 250.40bn | 8.73tn | 18.73k | 34.26 | 5.24 | 27.70 | 4.96 | 130.86 | 130.86 | 918.60 | 855.86 | 0.5913 | 1.01 | 3.73 | 93,883,960.00 | 8.43 | 4.99 | 10.51 | 6.14 | 76.11 | 69.10 | 14.26 | 9.94 | 2.24 | -- | 0.0589 | 51.87 | 25.28 | 11.49 | 85.90 | 16.67 | 13.01 | 16.47 |
| Chugai Pharmaceutical Co Ltd | 1.14tn | 386.96bn | 10.72tn | 7.60k | 27.15 | 5.83 | -- | 9.38 | 235.14 | 235.14 | 694.16 | 1,094.71 | 0.5877 | 1.22 | 3.56 | 150,230,100.00 | 19.91 | 19.29 | 22.95 | 23.91 | 70.48 | 63.57 | 33.87 | 28.39 | 4.80 | -- | 0.00 | 40.14 | -11.78 | 13.90 | -13.08 | 28.61 | -0.8947 | 27.23 |
Data as of Nov 22 2024. Currency figures normalised to Astellas Pharma Inc's reporting currency: Japanese Yen JPY
27.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 07 Nov 2024 | 115.88m | 6.40% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 64.59m | 3.57% |
| BlackRock Fund Advisorsas of 28 Jun 2024 | 62.14m | 3.43% |
| Nikko Asset Management Co., Ltd.as of 08 Nov 2024 | 51.69m | 2.86% |
| Daiwa Asset Management Co. Ltd.as of 31 Oct 2024 | 50.24m | 2.78% |
| BlackRock Japan Co. Ltd.as of 28 Jun 2024 | 37.93m | 2.10% |
| Wellington Management Co. LLPas of 08 Nov 2024 | 33.53m | 1.85% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 29.68m | 1.64% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 09 Oct 2023 | 28.61m | 1.58% |
| Geode Capital Management LLCas of 14 Nov 2024 | 18.98m | 1.05% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
